Kuldeep DhamaKhan SharunRuchi TiwariMaryam DadarYashpal Singh MalikKaram Pal SinghWanpen ChaicumpaRazi Vaccine & Serum Research Institute, IranCollege of Veterinary Science IndiaFaculty of Medicine, Siriraj Hospital, Mahidol UniversityIndian Veterinary Research Institute2020-05-052020-05-052020-01-01Human Vaccines and Immunotherapeutics. (2020)2164554X216455152-s2.0-85082179834https://repository.li.mahidol.ac.th/handle/20.500.14594/54584© 2020, © 2020 Taylor & Francis Group, LLC. The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection.Mahidol UniversityImmunology and MicrobiologyMedicinePharmacology, Toxicology and PharmaceuticsReviewSCOPUS10.1080/21645515.2020.1735227